{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T00:09:52Z","timestamp":1758845392565,"version":"3.44.0"},"reference-count":5,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2011,7,1]],"date-time":"2011-07-01T00:00:00Z","timestamp":1309478400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2011,7,1]],"date-time":"2011-07-01T00:00:00Z","timestamp":1309478400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacionline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Allergy and Clinical Immunology"],"published-print":{"date-parts":[[2011,7]]},"DOI":"10.1016\/j.jaci.2011.02.024","type":"journal-article","created":{"date-parts":[[2011,6,30]],"date-time":"2011-06-30T07:16:24Z","timestamp":1309418184000},"page":"219-221","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Topical intranasal ioxaglate meglumine 39.3% and ioxaglate sodium 19.6% (Hexabrix) reduces the acute response to nasal challenge with allergen"],"prefix":"10.1016","volume":"128","author":[{"given":"Shilpa","family":"Vishwanath","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fuad M.","family":"Baroody","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohamad R.","family":"Chaaban","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcella","family":"deTineo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenneth H.","family":"Lasser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elliot C.","family":"Lasser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert M.","family":"Naclerio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaci.2011.02.024_bib1","unstructured":"Hexabrix (ioxaglate meglumine\/ioxaglate sodium)\u2014description and clinical pharmacology. Available at: http:\/\/www.druglib.com\/druginfo\/hexabrix\/description_pharmacology\/. Accessed March 3, 2011."},{"key":"10.1016\/j.jaci.2011.02.024_bib2","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1148\/100.3.683","article-title":"Histamine release by contrast media","volume":"100","author":"Lasser","year":"1974","journal-title":"Radiology"},{"key":"10.1016\/j.jaci.2011.02.024_bib3","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1159\/000053640","article-title":"The multipotential pseudoantigenicity of x-ray contrast media. Pseudoantigen excess may down regulate the release of hypotensive mediators","volume":"123","author":"Lasser","year":"2000","journal-title":"Int Arch Allergy Immunol"},{"issue":"suppl\u00a01","key":"10.1016\/j.jaci.2011.02.024_bib4","doi-asserted-by":"crossref","first-page":"S72","DOI":"10.1016\/S1076-6332(03)80401-4","article-title":"Mechanisms of blood pressure change after bolus injections of x-ray contrast media","volume":"9","author":"Lasser","year":"2002","journal-title":"Acad Radiol"},{"key":"10.1016\/j.jaci.2011.02.024_bib5","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/S1521-6616(03)00155-4","article-title":"FcepsilonRI-FcgammaRII coaggregation inhibits IL-16 production from human Langerhans-like dendritic cells","volume":"108","author":"Kepley","year":"2003","journal-title":"Clin Immunol"}],"container-title":["Journal of Allergy and Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091674911003496?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091674911003496?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T08:27:28Z","timestamp":1758788848000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0091674911003496"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,7]]},"references-count":5,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2011,7]]}},"alternative-id":["S0091674911003496"],"URL":"https:\/\/doi.org\/10.1016\/j.jaci.2011.02.024","relation":{},"ISSN":["0091-6749"],"issn-type":[{"type":"print","value":"0091-6749"}],"subject":[],"published":{"date-parts":[[2011,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Topical intranasal ioxaglate meglumine 39.3% and ioxaglate sodium 19.6% (Hexabrix) reduces the acute response to nasal challenge with allergen","name":"articletitle","label":"Article Title"},{"value":"Journal of Allergy and Clinical Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaci.2011.02.024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2011 American Academy of Allergy, Asthma & Immunology. Published by Mosby, Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}